REVIUM Rx. (RVRC) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$732.00K; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$739.00K; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$938.00K; Depreciation and amortization (m).
- 2025-03-31: Basis Reported; EBITDA (m); Operating income -$737.00K; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$732.00K | (m) | (m) | (m) | (m) | -$626.00K* | (m) | $443.00K | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$739.00K | (m) | (m) | (m) | (m) | -$541.00K | (m) | $473.00K | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$938.00K | (m) | (m) | (m) | (m) | -$759.00K* | (m) | $391.00K | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$737.00K | (m) | (m) | (m) | (m) | -$357.00K | (m) | $218.00K | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|